Why do we need registries for patients treated with CAR T therapy?

The Lymphoma Hub are pleased to present a series of expert interviews from the 2nd European CAR T Cell Meeting in Sitges, ES. In this video, Christian Chabannon, University of Aix-Marseille, Marseille, FR, explains why we need registries for patients treated with CAR T therapy.

Christian Chabannon explains registries will allow us to fully measure the actual medical value of this novel product and to observe the long-term effect of CARs as they were approved based on mostly phase I/II trials with a limited number of patients.